Antigenics Reports Positive Trial Results By: MarketMinute.com Stock News June 03, 2009 at 13:24 PM EDT Shares of Antigenics Inc. (Nasdaq: AGEN) soared $1.25 to $2.78 after the drug research company reported positive results for its treatment of patients with kidney cancer.